Pages
Products

In Vivo Pharmacology for Oligonucleotides and CGT

OverviewHumanized ModelsHumanization StrategiesWorkflowFAQ

Humanized mouse models for siRNA, ASO, AOC, AAV and CAR-T evaluation — with target, effector and PK humanization

Species differences can make conventional animal models uninformative for human-specific molecules: an siRNA or ASO designed against a human sequence may find no fully complementary target transcript, and a human CAR may not recognize a murine antigen. We provide humanized mouse models and integrated in vivo pharmacology services to enable the evaluation of oligonucleotide therapeutics and cell and gene therapeutics (CGT)—from target engagement to functional and pharmacological readouts.

Why Is Human-Relevant In Vivo Pharmacology Important? 

Before entering clinical development, oligonucleotide therapeutics and CGT products require in vivo evaluation of therapeutic activity, target modulation, tissue distribution, and pharmacological responses.

Whether these data are interpretable depends on one condition: the animal model must reproduce the molecular interactions required by the MOA of the candidate drug. When it does not, efficacy, dose-response and target engagement readouts can be limited or misleading, regardless of how carefully species differences are noted in analysis.

Where Do Conventional Animal Models Fall Short?

The failure mode differs by therapeutic modality and mechanism of action.

Oligonucleotide Therapeutics

  • A human-specific siRNA and ASO may find no fully complementary orthologs.
  • Sequence mismatches may reduce target knockdown efficiency, even when the protein is conserved.
  • Target expression may vary between species.
  • Tissue distribution may not match the human profile.

Cell and Gene Therapeutics (CGT)

  • A human CAR or bispecific binder may not recognize the murine antigen.
  • Receptor differences may limit cell binding and activation.
  • Immune-component differences can alter persistence and safety profiles.
  • Species-specific interactions can change therapeutic cell behavior in vivo.

The Key Challenge

A suitable preclinical model must reproduce the biological components required for the candidate drug to engage its target and generate interpretable pharmacological responses.

Humanized Animal Models as a Solution

Humanized animal models help overcome some of the species-related constraints by incorporating relevant human biological components in an animal background. Depending on the research purposes, these can be therapeutic targets in humans, receptors for delivery, disease-associated genes or immune components.

Instead of applying humanization as a universal approach, we select model configurations based on the target specificity, mechanism of action, delivery requirements and intended pharmacological endpoints of the candidate drug. Each project starts with a model strategy proposal specifying the humanization approach, control groups, readouts and decision points.

Our Model Development and Pharmacology Capabilities

Target-Specific Model Solutions

Model selection and development across cardiometabolic, adipose, neuromuscular, CNS, and immuno-oncology research areas.

Model Characterization

Assessment of human target expression, tissue distribution, and relevant biological functions.

Integrated Pharmacology Support

In vivo efficacy evaluation, target modulation, tissue analysis, and PK/PD assessment where applicable.

Target Areas and Model Applications 

We support model selection and in vivo pharmacology evaluation across two major therapeutic categories.

Oligonucleotides · Hepatic & Metabolic

Target Therapeutic Application Recommended Humanized Configuration Key Readouts
LPA Elevated Lp(a); cardiovascular risk Human LPA transgenic model; additional human APOB background if required Plasma Lp(a), apo(a) protein, LPA mRNA suppression
INHBE Obesity; fat-selective weight management Humanized INHBE knock-in; optional combination with humanized ALK7 Hepatic INHBE mRNA, circulating Activin E, body weight, fat and lean mass
ALK7 / ACVR1C Obesity; adipose tissue regulation Humanized ALK7 knock-in model Adipose hALK7 mRNA knockdown, body composition, metabolic parameters
PCSK9 Hypercholesterolemia; LDL-C reduction Humanized PCSK9 model; conventional model only when candidate cross-reactivity is confirmed and scientifically justified. Plasma PCSK9, LDL-C, total cholesterol
APOC3 Hypertriglyceridemia; dyslipidemia Human APOC3 transgenic/humanized model; conventional model only when candidate cross-reactivity is confirmed and scientifically justified. Plasma APOC3, triglycerides, lipid profile
ANGPTL3 Dyslipidemia; triglyceride and LDL-C regulation Humanized ANGPTL3 model; conventional model only when candidate cross-reactivity is confirmed and scientifically justified. Plasma ANGPTL3, triglycerides, LDL-C, lipid profile

Oligonucleotides · Extrahepatic & Neuromuscular

Target / Biological Component Therapeutic Application Recommended Humanized Configuration Key Readouts
TFR1 + DMPK DM1; muscle-targeted oligonucleotide delivery Humanized TfR1 combined with DMSXL human DMPK disease model Muscle mutant DMPK RNA, RNA foci, alternative splicing correction
PRNP / PrP Prion diseases; CNS-targeted oligonucleotide therapeutics Human PRNP transgenic or humanized mouse model Brain and spinal cord PrP mRNA/protein, tissue distribution, disease-associated endpoints

CGT · In Vivo CAR-T & Solid Tumors

Target Therapeutic Application Recommended Humanized Configuration Key Readouts
CD19 In vivo CAR-T for B-cell malignancies HSC-humanized immune system with human T- and B-cell compartments; CD19-positive tumor model where required CAR-positive human T-cell frequency, B-cell depletion, tumor burden, human cytokines
BCMA CAR-T for multiple myeloma BCMA-positive myeloma xenograft; PBMC- or HSC-humanized background according to study objectives Tumor burden, CAR-T expansion and persistence, BCMA expression, cytokine profiles
CLDN18.2 CAR-T for gastric and pancreatic cancers Cross-reactive mouse target model with CLDN18.2-positive tumor models; humanized target model if needed Tumor growth inhibition, CAR-T infiltration, gastric tissue injury, on-target/off-tumor effects
GPC3 CAR-T for hepatocellular carcinoma GPC3-positive tumor xenograft; humanized target model where required Tumor burden, CAR-T infiltration, target expression, survival
MSLN CAR-T for mesothelin-positive solid tumors MSLN-positive tumor xenograft; humanized target model where required Tumor burden, CAR-T expansion, target expression, normal tissue effects

Immune System Humanization Platforms

Model Platform Therapeutic Application Model Configuration Key Readouts
PBMC-Humanized Model CAR-T and TCE efficacy evaluation Human PBMC-engrafted immunodeficient mice, combined with antigen-positive tumor models where appropriate Human T-cell activation and expansion, CAR-T activity, tumor growth inhibition, cytokine release
HSC-Humanized Model In vivo CAR-T generation and immune system-related evaluation Human HSC-engrafted mice with reconstituted human immune cell compartments; tumor models where required Human T-cell development, CAR-positive cell frequency, B-cell depletion, tumor burden, human cytokines

Model configurations are selected according to drug-target compatibility, species cross-reactivity, and study objectives. Humanized target, immune system, and disease model components may be combined when required.

Humanization Strategies for Different Pharmacological Questions

The appropriate humanization strategy depends on the drug's target specificity, mechanism of action, delivery route, and the biological context required for efficacy evaluation.

Endogenous Gene Humanization

Endogenous Gene Humanization

Human target sequences are introduced into the corresponding mouse gene locus, enabling expression under endogenous regulatory elements.

Suitable for: Human-specific siRNA/ASO candidates, human receptors, and targets requiring physiologically regulated expression.

AAV-Mediated Human Gene Expression

AAV-Mediated Human Gene Expression

AAV vectors deliver human target genes to selected tissues or cell populations to establish human gene expression in vivo.

Suitable for: Rapid proof-of-concept studies, selected tissue-specific targets, and disease-model combinations where stable germline humanization is not essential.

Multi-Component Humanization

Multi-Component Humanization

Multiple human-specific components are incorporated into one model to address drug delivery, target recognition, and disease biology simultaneously.

Suitable for: Receptor-mediated oligonucleotide delivery, multi-target therapies, and complex pharmacological mechanisms.

Fc Receptor and FcRn Humanization

Fc Receptor and FcRn Humanization

When a candidate depends on Fc-mediated effector function or FcRn-driven half-life extension, humanization extends beyond the target to Fc receptors and FcRn. Model configurations include hFcγR humanized mice for in vivo effector-function ranking, hFcRn humanized mice for FcRn-dependent PK, and hFcRn × immunodeficient backgrounds to separate FcRn effects from ADA interference.

Suitable for: Fc-engineered antibodies, Fc-containing CAR constructs, T-cell engagers, and antibody-oligonucleotide conjugates (AOC).

How Do We Select the Right Model?

Model Characterization & Pharmacological Relevance

Humanized models are characterized beyond gene expression to confirm target expression, biological function, and pharmacological relevance.

Molecular Characterization

  • Human-specific gene and protein expression
  • Tissue distribution and expression consistency

Functional Characterization

  • Receptor-ligand binding and target recognition
  • Downstream signaling and biological activity

Pharmacological Characterization

  • Target engagement and modulation
  • Dose-dependent responses and relevant PD endpoints

Characterization strategies are tailored to the target, model configuration, and therapeutic modality to support reliable in vivo pharmacology evaluation.

Integrated In Vivo Pharmacology Workflow

02

Model preparation

  • Humanized colony expansion and expression validation, or AAV vector construction and in vivo expression confirmation.
04

PK/PD and tissue analysis

  • Target mRNA/protein quantification, tissue distribution, dose-response relationship.
01

Target assessment and strategy proposal

  • We review your target sequence, human-mouse homology, delivery receptor compatibility, and indication background.
03

Efficacy study design and execution

  • Dosing regimen, timepoints, tissue collection, and readout selection aligned with your clinical plan.
05

IND-enabling reporting

  • Methodology descriptions, internal control justification, and data interpretation suitable for regulatory submission.

Frequently Asked Questions 

When is a humanized animal model necessary for small nucleic acid drug evaluation?

A humanized model may be required when a candidate siRNA or ASO specifically recognizes the human target sequence but has low activity against the corresponding mouse gene. If the candidate has adequate activity against the animal target, a conventional model may be sufficient, depending on the study objective.

What is the difference between an AAV-mediated model and a gene-humanized model?

Gene-humanized models replace the endogenous mouse locus with human sequences, preserving native regulatory control. AAV-mediated models deliver human genes episomally, which can be faster but may not replicate physiological expression or regulation.

Can one humanized model be used for both efficacy and safety evaluation?

Not always. A model that is appropriate for assessing target knockdown or antitumor efficacy may not recapitulate human immune interactions or normal-tissue toxicity. Each pharmacological or safety question should be evaluated separately for model suitability.

How do you evaluate whether a humanized model is pharmacologically relevant?

Evaluation may include: human-specific mRNA and protein expression, tissue distribution, functional target recognition, downstream pathway activity, and response to reference compounds or therapeutic candidates.

Discuss Your Humanized Model Requirements

Share your target, therapeutic modality, and study objectives with our team to explore suitable model strategies and in vivo evaluation plans.

Quick Inquiry